Drug-Resistant Germs Lure Biotechs to Create New Antibiotics

Optimer Pharmaceuticals Inc.’s Dificid is on track to lead as many as five new antibiotics onto the market over the next three years as a surge in drug-resistant germs stokes the need for new medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.